Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$12.2 million.

  • ImmunityBio's Cash from Investing Activities fell 378.88% to -$181.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 825.52%. This contributed to the annual value of -$12.2 million for FY2024, which is 59.81% up from last year.
  • According to the latest figures from FY2024, ImmunityBio's Cash from Investing Activities is -$12.2 million, which was up 59.81% from -$30.5 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Cash from Investing Activities peaked at $27.3 million during FY2022, and registered a low of -$84.9 million during FY2021.
  • Over the past 3 years, ImmunityBio's median Cash from Investing Activities value was -$12.2 million (recorded in 2024), while the average stood at -$5.1 million.
  • Per our database at Business Quant, ImmunityBio's Cash from Investing Activities tumbled by 328.46% in 2021 and then skyrocketed by 132.16% in 2022.
  • ImmunityBio's Cash from Investing Activities (Yearly) stood at -$19.8 million in 2020, then slumped by 328.46% to -$84.9 million in 2021, then spiked by 132.16% to $27.3 million in 2022, then tumbled by 211.62% to -$30.5 million in 2023, then skyrocketed by 59.81% to -$12.2 million in 2024.